Top Ten most popular articles on this week

pharmafile | August 10, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ADHD, Allergan, MHRA, UK, brexit, iraq, pharma, top 10 

There was some clarity on Brexit this week as the MHRA set out a plan for the implantation period set to begin in March 2019. However the murky depths of the pharma industry came to the surface as US congressman Chris Collins was arrested for insider trading while a court case opened by the families of veterans alleged that pharma giants had funded terror in Iraq. 

Meanwhile England’s most senior GP resigned over inflammatory online comments while Allergan filed legal action against Pfizer over the opioid crisis. There was more bad news for patients using valsartan as the FDA expanded the list of recalls. However an exciting Phase 3 clinical trial led by researchers at Queen Mary University, London shed light into the ways in which patients might be able to develop a new immune system through the use of stem cell transplants.

So for the latest pharmaceutical news and updates, check out this week’s ten most popular articles on now!

10. Lawsuit alleges pharma giants funded terror in Iraq

The United States Justice Department is investigating claims that major pharmaceutical and medical device companies were aware that supplies that they gave to the Iraqi government would be used to fund terror attacks against American troops.

9. FDA expands list of valsartan recalls

The US Food and Drug Administration (FDA) has expanded a list of products containing valsartan that are to be recalled.

8. Almirall picks up Allergan’s dermatology portfolio to for $650m

Allergan has sealed a deal to sell its dermatology portfolio, comprising five brands, to Spanish pharmaceutical firm Almirall for $650 million in cash.

7. Allergan sues Pfizer over opioid crisis lawsuits

Allergan are suing American pharma giant Pfizer over potential damages that they may be forced to pay relating to hundreds of lawsuits that have been filed against them over their alleged role in the opioid crisis.

6. Stem cells could ‘reset’ immune system in Crohn’s disease patients

A clinical trial led by researchers at Queen Mary University, London is looking into ways in which patients with Crohn’s disease could ‘grow’ a new immune system through the use of stem cell transplants.

5. Drugs should be preferred first-choice treatment for ADHD

Ritalin and other amphetamines should be the preferred first-choice medications for the short-term treatment of ADHD, according to a study published in the Lancet Psychiatry Journal.

4. US Congressman arrested over insider trading in biopharma firm

A Republican Congressman has been arrested by the FBI over on charges of insider trading with shares in Australian biopharmaceutical firm Innate Immunotherapeutics, a company for which he served as a board member.

3. Strong efficacy but serious side-effects with Spark’s haemophilia drug drop shares by 30%

Spark Therapeutics has been left reeling after it revealed new data on its haemophilia A treatment, which, while promising in efficacy, left investors disappointed and share price plummeting.

2. England’s top GP resigns over imflammatory online comments

England’s most senior General Practitioner and Director of Primary Care and Deputy Medical Director at NHS England has resigned over inflammatory comments he made anonymously on an online medical forum.

1. MHRA sets out Brexit implementation period plan

The UK Medicines and Healthcare products Regulatory Agency (MHRA) have released an update which sets out what pharmaceutical and healthcare companies should expect from the Brexit implementation period that will run from March 2019 to December 2020.

Related Content


AbbVie’s Aquipta receives MHRA marketing authorisation

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the …

Latest content